GALACTIC HF

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

Stage
klaar
Medicine
omecamtiv mecarbil
Population
Hartfalen
Phase
III
First Patient In
6 July 2017
Last Patient In
28 June 2019
Last Patient Last Visit
30 September 2020

National Lead

prof. dr. A. Voors

Cardioloog

Study Director

dr. J. Schaap

Cardioloog

The page has expired.